hackint0sh/temp-data huggingface dataset:
protocolSection identificationModule nctId: NCT06279338, orgStudyIdInfo id: [2023] No.0969, briefTitle: A Novel Conditioning Regimen for Myelodysplastic Syndrome With Moderate High IPSS-M Score, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-03-01, primaryCompletionDateStruct date: 2026-01-31, completionDateStruct date: 2026-01-31, studyFirstPostDateStruct date: 2024-02-28, lastUpdatePostDateStruct date: 2024-02-28, sponsorCollaboratorsModule leadSponsor name: Wuhan Union Hospital, China, class: OTHER, descriptionModule briefSummary: Figure out the Efficacy and Safety of Azacitidine Combined with BUCY2 Conditioning Regimen Before Allogeneic Hematopoietic Stem Cell Transplantation for Myelodysplastic Syndrome with Moderate High IPSS-M Score, conditionsModule conditions: Myelodysplastic Syndromes, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 40, type: ESTIMATED, armsInterventionsModule interventions name: Azacitidine Injection, outcomesModule primaryOutcomes measure: Progression-free survival (PFS) at 18 months post-transplant, month, secondaryOutcomes measure: Overall survival (OS) at 18 months post-transplant, month, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06279312, orgStudyIdInfo id: N202311065, briefTitle: The Effect of Adaptogen Elixir on Sleep Improvement, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-02-26, primaryCompletionDateStruct date: 2024-07-31, completionDateStruct date: 2024-12-31, studyFirstPostDateStruct date: 2024-02-28, lastUpdatePostDateStruct date: 2024-03-15, sponsorCollaboratorsModule leadSponsor name: TCI Co., Ltd., class: INDUSTRY, descriptionModule briefSummary: This study aims to examine the effectiveness of Adaptogen Elixir herbal drink in relieving emotions and improving sleep quality. Participants will be randomly assigned to either the placebo group or the Adaptogen Elixir herbal drink group, with 25 participants in each group. On the day of the experiment (week 0), participants are required to collect blood and saliva samples, fill out questionnaires assessing sleep disorders and stress condition, and use a sleep monitoring system to track their sleep and autonomic nervous system conditions. Subsequently, participants will be given the experimental samples and instructed to consume them continuously for 4 weeks following the instruction. Follow-up assessments will be conducted in the 2nd and 4th weeks, participants are required to collect blood and saliva samples, fill out questionnaires assessing sleep disorders and stress condition, and use a sleep monitoring system to track their sleep and autonomic nervous system conditions., conditionsModule conditions: Sleep Disorder, conditions: Anxiety Disorders, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: OTHER, maskingInfo masking: DOUBLE, whoMasked: PARTICIPANT, whoMasked: INVESTIGATOR, enrollmentInfo count: 50, type: ESTIMATED, armsInterventionsModule interventions name: Placebo drink, interventions name: Adaptogen Elixir drink, outcomesModule primaryOutcomes measure: Sleep monitoring, primaryOutcomes measure: Sleeping qualityy, primaryOutcomes measure: Sleeping disorders, secondaryOutcomes measure: Neuropeptide Y concentration, secondaryOutcomes measure: Cortisol concentration, secondaryOutcomes measure: Anxiety, secondaryOutcomes measure: Low Frequency/High Frequence (LF/HF) ratio, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 65 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Taipei Medical University, status: RECRUITING, city: Taipei, country: Taiwan, contacts name: Hsin-Chien Lee, Doctor, role: CONTACT, phone: +886-02-22490088, phoneExt: 79213/8158, email: ellalee@tmu.edu.tw, geoPoint lat: 25.04776, lon: 121.53185, hasResults: False
protocolSection identificationModule nctId: NCT06279299, orgStudyIdInfo id: LLND, briefTitle: Lateral Pelvic Lymph Node Dissection for Rectal Neuroendocrine Neoplasms Undergoing Laparoscopic Total Mesenteric Excision, statusModule overallStatus: RECRUITING, startDateStruct date: 2022-08-01, primaryCompletionDateStruct date: 2028-08-01, completionDateStruct date: 2028-08-01, studyFirstPostDateStruct date: 2024-02-28, lastUpdatePostDateStruct date: 2024-02-28, sponsorCollaboratorsModule leadSponsor name: National Cancer Center, China, class: OTHER, descriptionModule briefSummary: The purpose of this study is to investigate the metastatic status of lateral pelvic lymph nodes in rectal neuroendocrine neoplasms (rNENs) undergoing laparoscopic total mesenteric excision (TME). The hypothesis is that the rate of lateral lymph node metastasis is underestimated in rNENs undergoing TME, necessitating concurrent lateral Pelvic lymph node dissection., conditionsModule conditions: Rectal Neuroendocrine Neoplasm, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 30, type: ESTIMATED, armsInterventionsModule interventions name: lateral pelvic lymph node dissection, outcomesModule primaryOutcomes measure: The rate of lateral pelvic lymph node metastasis, secondaryOutcomes measure: The rate of lymph node metastasis, secondaryOutcomes measure: Disease-free survival rate, secondaryOutcomes measure: Overall survival rate, secondaryOutcomes measure: Locoregional recurrence free survival rate, secondaryOutcomes measure: Radical resection (R0), eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 75 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: National Cancer Center, status: RECRUITING, city: Beijing, state: Beijing, zip: 100000, country: China, contacts name: Haitao Zhou, M.D., role: CONTACT, phone: +8613381167333, email: zhouhaitao01745@163.com, contacts name: Yueyang Zhang, M.D., role: CONTACT, phone: +8613552910035, email: yyzhang0129@163.com, geoPoint lat: 39.9075, lon: 116.39723, hasResults: False
protocolSection identificationModule nctId: NCT06279247, orgStudyIdInfo id: KYLL-202212-011, briefTitle: Proteomics and Metabolomics of Body Fluid in Patients With Narcolepsy, statusModule overallStatus: RECRUITING, startDateStruct date: 2022-09-01, primaryCompletionDateStruct date: 2024-09, completionDateStruct date: 2024-09, studyFirstPostDateStruct date: 2024-02-28, lastUpdatePostDateStruct date: 2024-03-15, sponsorCollaboratorsModule leadSponsor name: Qilu Hospital of Shandong University, class: OTHER, descriptionModule briefSummary: Narcolepsy (NRL) is a rare chronic central nervous system dysfunction disease, which is more common in children and adolescents, and less common in adults. Its typical clinical features include excessive daytime sleep, paroxysmal cataplexy, sleep paralysis and sleep hallucination. In addition to the above typical manifestations, patients with narcolepsy can also manifest as hyperappetite, weight gain, multiple dreams, sleep fragmentation, anxiety and depression and other emotional disorders. In particular, in narcolepsy type 1 with cataplexy, cataplexy episodes can be confused with falls caused by seizures, transient ischemic attacks or neuromuscular disorders, or even mental conversion disorders. Due to its diverse clinical symptoms, it is easy to be missed and misdiagnosed.At present, the pathogenesis of narcolepsy is still unclear, and its pathogenesis may be related to immune, genetic, environmental, infection, central nervous system degeneration and other factors. This study aims to investigate the changes of body fluid proteomics and metabolomics in patients with narcolepsy, and to provide an important basis for the pathogenesis of narcolepsy., conditionsModule conditions: Narcolepsy, designModule studyType: OBSERVATIONAL, designInfo observationalModel: CASE_CONTROL, timePerspective: CROSS_SECTIONAL, enrollmentInfo count: 60, type: ESTIMATED, armsInterventionsModule, outcomesModule primaryOutcomes measure: To screen potential molecular markers related to the biological characteristics and prognosis of narcolepsy., eligibilityModule sex: ALL, minimumAge: 5 Years, maximumAge: 100 Years, stdAges: CHILD, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Qilu Hospital of Shandong University, status: RECRUITING, city: Jinan, state: Shandong, zip: 250012, country: China, contacts name: Wenjing Jiang, role: CONTACT, phone: 18560082210, email: jiangwenjing@qiluhospital.com, geoPoint lat: 36.66833, lon: 116.99722, hasResults: False
protocolSection identificationModule nctId: NCT06279234, orgStudyIdInfo id: C4001002, briefTitle: A Study to Learn How Different Amounts of PF-06954522 Are Tolerated and Act in Adults With Type 2 Diabetes Mellitus, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-02-20, primaryCompletionDateStruct date: 2024-12-31, completionDateStruct date: 2024-12-31, studyFirstPostDateStruct date: 2024-02-28, lastUpdatePostDateStruct date: 2024-04-11, sponsorCollaboratorsModule leadSponsor name: Pfizer, class: INDUSTRY, descriptionModule briefSummary: The purpose of the study is to evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of multiple escalating oral doses of PF-06954522 in adult participants with inadequately controlled type 2 diabetes mellitus (T2DM) on metformin (Part A) and optionally in non-diabetic participants with obesity (Part B)., conditionsModule conditions: Type 2 Diabetes Mellitus (T2DM), conditions: Obesity, designModule studyType: INTERVENTIONAL, phases: PHASE1, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: BASIC_SCIENCE, maskingInfo masking: NONE, enrollmentInfo count: 122, type: ESTIMATED, armsInterventionsModule interventions name: Placebo, interventions name: Rosuvastatin, interventions name: Midazolam, interventions name: Omeprazole, interventions name: PF-06954522, outcomesModule primaryOutcomes measure: Number of Participants Reporting Adverse Events, primaryOutcomes measure: Number of Participants with Clinically Significant Change From Baseline in Laboratory Abnormalities, primaryOutcomes measure: Number of Participants With Clinically Significan Change From Baseline in Vital Signs, primaryOutcomes measure: Number of Participants With Clinically Significant Change From Baseline in 12-Lead ECGs, primaryOutcomes measure: Number of Participants with categorical scores on the Columbia Suicide Severity Rating Scale (C-SSRS), primaryOutcomes measure: Number of Participants With Change From Baseline in Physical Examination, secondaryOutcomes measure: Maximum Observed Plasma Concentration (Cmax), secondaryOutcomes measure: Area Under the Curve from Time Zero to end of dosing interval (AUCtau), secondaryOutcomes measure: Time to Reach Maximum Observed Plasma Concentration (Tmax), secondaryOutcomes measure: Plasma Decay Half-Life (t1/2), secondaryOutcomes measure: Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau), secondaryOutcomes measure: Percentage of Dose of PF-06751979 Excreted Unchanged in the Urine Over the Dosing Interval Tau (Aetau%), secondaryOutcomes measure: Renal Clearance (CLr), eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 70 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Anaheim Clinical Trials, LLC, status: RECRUITING, city: Anaheim, state: California, zip: 92801, country: United States, geoPoint lat: 33.83529, lon: -117.9145, locations facility: Qps-Mra, Llc, status: RECRUITING, city: South Miami, state: Florida, zip: 33143, country: United States, geoPoint lat: 25.7076, lon: -80.29338, hasResults: False
protocolSection identificationModule nctId: NCT06279221, orgStudyIdInfo id: B7981055, briefTitle: Litfulo Capsules Special Investigation, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04-30, primaryCompletionDateStruct date: 2030-06-25, completionDateStruct date: 2030-06-25, studyFirstPostDateStruct date: 2024-02-28, lastUpdatePostDateStruct date: 2024-02-28, sponsorCollaboratorsModule leadSponsor name: Pfizer, class: INDUSTRY, descriptionModule briefSummary: The objective of this Study is to confirm the safety during the long-term use of this drug and the effectiveness during the use of this drug under the actual use in the patients treated with this drug., conditionsModule conditions: Alopecia Areata, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 850, type: ESTIMATED, armsInterventionsModule interventions name: LITFULO, outcomesModule primaryOutcomes measure: Proportion of participants with adverse events (AEs), primaryOutcomes measure: Percentage of patients achieving SALT≤20 [SALT score (absolute value) 20 or less], eligibilityModule sex: ALL, minimumAge: 12 Years, stdAges: CHILD, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06279208, orgStudyIdInfo id: 2023-A00272-43, briefTitle: Phosphoproteomic Profile of Children With Down Syndrome, acronym: PEPS, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-03-18, primaryCompletionDateStruct date: 2024-09, completionDateStruct date: 2024-09, studyFirstPostDateStruct date: 2024-02-28, lastUpdatePostDateStruct date: 2024-04-01, sponsorCollaboratorsModule leadSponsor name: Perha Pharmaceuticals, class: INDUSTRY, collaborators name: Proteas Bioanalytics, collaborators name: Göteborg University, descriptionModule briefSummary: One of the major causes of cognitive disorders limiting the learning abilities of children with Down's syndrome is excess activity of the DYRK1A protein kinase, whose gene is located on chromosome 21. Consequently, variations in the level of phosphorylation, and hence activity, of DYRK1A target proteins involved in synaptic transmission, could identify mechanisms underlying these cognitive disorders.Several studies have shown that plasma proteins can reflect a pathophysiological brain state. The investigators plan to carry out a phosphoproteomic study to determine the phosphorylation profile of plasma proteins in children with Down's syndrome, and identify potential DYRK1A-dependent pathophysiological mechanisms and biomarkers involved in the natural course of cognition in children with Down's syndrome., conditionsModule conditions: Down Syndrome, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 60, type: ESTIMATED, armsInterventionsModule interventions name: Blood sample, outcomesModule primaryOutcomes measure: Phosphoproteomic profile, secondaryOutcomes measure: Identification of brain proteins, secondaryOutcomes measure: Impact of environnement on phosphoproteomic profile, secondaryOutcomes measure: Impact of DYRK1A on Down Syndrome specific proteomic profile, eligibilityModule sex: MALE, minimumAge: 6 Years, maximumAge: 12 Years, stdAges: CHILD, contactsLocationsModule locations facility: CHU Grenoble, status: NOT_YET_RECRUITING, city: Grenoble, country: France, contacts name: Dr Marey, role: CONTACT, phone: 0476767285, geoPoint lat: 45.16667, lon: 5.71667, locations facility: Hospices Civils de Lyon, status: RECRUITING, city: Lyon, country: France, contacts name: Dr Sanlaville, role: CONTACT, phone: 0427855573, geoPoint lat: 45.74848, lon: 4.84669, locations facility: Institut Jérôme Lejeune, status: RECRUITING, city: Paris, country: France, contacts name: Dr Cieuta-Walti, role: CONTACT, phone: 0156586300, geoPoint lat: 48.85341, lon: 2.3488, locations facility: CHU Rennes, status: RECRUITING, city: Rennes, country: France, contacts name: Dr Jean-Marçais, role: CONTACT, phone: 0299266744, geoPoint lat: 48.11198, lon: -1.67429, locations facility: CHU Saint-Etienne, status: NOT_YET_RECRUITING, city: Saint-Etienne, country: France, contacts name: Dr Touraine, role: CONTACT, phone: 0477828116, geoPoint lat: 45.43389, lon: 4.39, hasResults: False
protocolSection identificationModule nctId: NCT06279195, orgStudyIdInfo id: EH23-326, briefTitle: Phenotyping of Idiopathic Pelvic Pain With Real-time Uterine Imaging and Relugolix-Combination Therapy Treatment, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04-05, primaryCompletionDateStruct date: 2025-08-02, completionDateStruct date: 2025-08-02, studyFirstPostDateStruct date: 2024-02-26, lastUpdatePostDateStruct date: 2024-02-28, sponsorCollaboratorsModule leadSponsor name: NorthShore University HealthSystem, class: OTHER, collaborators name: Pfizer, descriptionModule briefSummary: The mechanisms underlying variable efficacy of Relugolix-Combination Therapy (REL-CT) in mitigating unexplained pelvic pain will be evaluated with uterine imaging techniques and quantitative sensory testing., conditionsModule conditions: Pelvic Pain, designModule studyType: INTERVENTIONAL, phases: PHASE2, designInfo allocation: NON_RANDOMIZED, interventionModel: PARALLEL, interventionModelDescription: Participants in two groups with different conditions will be give REL-CT., primaryPurpose: BASIC_SCIENCE, maskingInfo masking: NONE, enrollmentInfo count: 60, type: ESTIMATED, armsInterventionsModule interventions name: Relugolix (40 mg) /estradiol (1 mg)/norethisterone acetate (0.5 mg) oral tablet, outcomesModule primaryOutcomes measure: Correlation between post-treatment pelvic pain and baseline uterine contraction frequency, primaryOutcomes measure: Correlation between post-treatment pelvic pain and baseline sensory hypersensitivity Z-score., eligibilityModule sex: FEMALE, minimumAge: 18 Years, maximumAge: 35 Years, stdAges: ADULT, contactsLocationsModule locations facility: NorthShore University HealthSystem, city: Evanston, state: Illinois, zip: 60201, country: United States, contacts name: Kevin Hellman, PhD, role: CONTACT, phone: 847-570-2622, email: khellman@northshore.org, geoPoint lat: 42.04114, lon: -87.69006, hasResults: False
protocolSection identificationModule nctId: NCT06279169, orgStudyIdInfo id: 2023-BRT-SBF-113355, briefTitle: The Effect of Heart Sound and White Noise on Pain and Physiological Parameters During Hepatitis B Vaccine Injection, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-04-24, primaryCompletionDateStruct date: 2025-08-29, completionDateStruct date: 2025-08-29, studyFirstPostDateStruct date: 2024-02-26, lastUpdatePostDateStruct date: 2024-04-26, sponsorCollaboratorsModule leadSponsor name: Bartın Unıversity, class: OTHER, descriptionModule briefSummary: It can cause physiological and behavioral changes in infants such as pain, tachycardia, hypoxemia, increased blood pressure, grimacing, prolonged crying, and irritability. Vaccination is an important part of neonatal nursing care. Newborns express their pain nonverbally and behaviorally. Therefore, any pain assessment is based on the ability of others to recognize pain symptoms. This randomized controlled trial was planned to evaluate the effect of heart sound and white noise on pain and physiological parameters during intramuscular injection of hepatitis B vaccine in newborns. This randomized controlled study used parallel trial design., conditionsModule conditions: Pain, Acute, conditions: Newborn; Vitality, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: SUPPORTIVE_CARE, maskingInfo masking: SINGLE, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 99, type: ESTIMATED, armsInterventionsModule interventions name: Heart Sound, interventions name: White Noise, outcomesModule primaryOutcomes measure: The Newborn Infant Pain Scale (NIPS), secondaryOutcomes measure: oxygen saturation, secondaryOutcomes measure: heart rate, secondaryOutcomes measure: Crying Time, eligibilityModule sex: ALL, minimumAge: 2 Days, maximumAge: 28 Days, stdAges: CHILD, contactsLocationsModule locations facility: Bartın University, status: RECRUITING, city: Bartın, country: Turkey, contacts name: Fatma Dinç, Asst.Prof., role: CONTACT, phone: +9005383555685, email: fatmadinc@bartin.edu.tr, contacts name: Aylin Kurt, Asst.Prof., role: CONTACT, phone: +9005382087211, email: aylinkurt67@gmail.com, geoPoint lat: 41.63583, lon: 32.3375, hasResults: False
protocolSection identificationModule nctId: NCT06279156, orgStudyIdInfo id: MTU-EC-IM-0-014/65, briefTitle: Optimal Frequency of Total Body Water Measurements by Bioelectrical Impedance Analysis to Prevent Intradialytic Hypotension, statusModule overallStatus: COMPLETED, startDateStruct date: 2022-06-01, primaryCompletionDateStruct date: 2023-02-28, completionDateStruct date: 2023-02-28, studyFirstPostDateStruct date: 2024-02-26, lastUpdatePostDateStruct date: 2024-03-06, sponsorCollaboratorsModule leadSponsor name: Thammasat University Hospital, class: OTHER, descriptionModule briefSummary: The goal of this clinical trial was to compare the efficiencies of bioelectrical impedance analysis (BIA) measurement frequency in preventing intradialytic hypotension in end-stage renal disease (ESRD) patients undergoing regular hemodialysis. The main question aimed to answer about the optimum frequency of BIA measurements to prevent intradialytic hypotension.Participants underwent BIA measurements to determine their appropriate dry weight, and factors affecting intradialytic hypotension.Researchers compared the efficiencies of BIA measurements between the every-1-month group and the every-2-month group to prevent intradialytic hypotension., conditionsModule conditions: Intradialytic Hypotension, conditions: End Stage Renal Disease on Dialysis, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: CROSSOVER, primaryPurpose: PREVENTION, maskingInfo masking: NONE, enrollmentInfo count: 94, type: ACTUAL, armsInterventionsModule interventions name: Bioelectrical Impedance Analysis (BIA), outcomesModule primaryOutcomes measure: incidence rate ratio of intra-dialytic hypotension of every-1-month BIA to every-2-month BIA, secondaryOutcomes measure: factors affecting intra-dialytic hypotension, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Thammasat University Hospital, city: Pathum Thani, zip: 12120, country: Thailand, geoPoint lat: 14.01346, lon: 100.53049, hasResults: False